Trial Profile

Impact of Biomarkers on Pharmacokinetics and Pharmacodynamics of Ticagrelor

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 05 Dec 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ticagrelor (Primary)
Indications Abdominal aortic aneurysm; Acute coronary syndromes; Angina pectoris; Cardiovascular disorders; Community-acquired pneumonia; Coronary artery disease; Sickle cell anaemia; Stroke
Focus Adverse reactions; Pharmacogenomic

Most Recent Events

30 Apr 2022 Results (n=175) assessing effect of genetic polymorphism Including NUP153 and SVEP1 on the pharmacokinetics and pharmacodynamics of Ticagrelor of healthy Chinese subjects published in the Clinical Drug Investigation
19 Dec 2020 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.
19 Dec 2020 Planned primary completion date changed from 1 Oct 2020 to 1 Oct 2021.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com